S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE

MLA

C Mayer, et al. “S119: Preliminary Results of a Phase 1 Study in Healthy Subjects Administered Inclacumab, a Fully Human Igg4 Anti-P-Selectin Monoclonal Antibody in Development for Treatment of Sickle Cell Disease.” HemaSphere, vol. 6, Jan. 2022, p. 10. EBSCOhost, https://doi.org/10.1097/01.HS9.0000821444.06029.7c.

APA

C Mayer, D Cooper, A Redfern, X Geng, J Shi, M Zutphen-van Geffen, I Kuan, K Koek, H Kastrissios, K Patel, M Davis, & P Yue. (2022). S119: Preliminary Results of a Phase 1 Study in Healthy Subjects Administered Inclacumab, a Fully Human Igg4 Anti-P-Selectin Monoclonal Antibody in Development for Treatment of Sickle Cell Disease. HemaSphere, 6, 10. https://doi.org/10.1097/01.HS9.0000821444.06029.7c

Chicago

C Mayer, D Cooper, A Redfern, X Geng, J Shi, M Zutphen-van Geffen, I Kuan, et al. 2022. “S119: Preliminary Results of a Phase 1 Study in Healthy Subjects Administered Inclacumab, a Fully Human Igg4 Anti-P-Selectin Monoclonal Antibody in Development for Treatment of Sickle Cell Disease.” HemaSphere 6 (January): 10. doi:10.1097/01.HS9.0000821444.06029.7c.